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Blood Pressure Is a Major Risk Factor for Renal Death
An Analysis of 560 352 Participants From the Asia-Pacific Region
Conall M. O’Seaghdha, Vlado Perkovic, Tai Hing Lam, Stella McGinn, Federica Barzi, Dong Feng Gu,
Alan Cass, Il Suh, Paul Muntner, Graham G. Giles, Hirotsugu Ueshima, Mark Woodward,
Rachel Huxley; on behalf of the Asia Pacific Cohort Studies Collaboration
Abstract—Chronic kidney disease is a major worldwide public health problem that causes substantial morbidity and
mortality. Studies from the Asia-Pacific region have reported some of the highest chronic kidney disease prevalence
rates in the world, but access to dialysis is limited in many countries, making it imperative to identify high-risk
individuals. We performed a participant-level data overview of prospective studies conducted in the Asia-Pacific region
to quantify the magnitude and direction of the associations between putative risk factors and renal death. Age- and
sex-adjusted Cox proportional hazards models were applied to pooled data from 35 studies to calculate hazard ratios
(95% CIs) for renal death associated with a standardized change in risk factors. Among 560 352 participants followed
for a median of 6.8 years, a total of 420 renal deaths were observed. Continuous and positive associations among systolic
blood pressure, diastolic blood pressure, fasting blood glucose, and total cholesterol levels with renal death were
observed, as well as a continuous but inverse association with high-density lipoprotein cholesterol. Systolic blood
pressure was the strongest risk factor for renal death with each SD increase in systolic blood pressure (19 mm Hg)
associated with 80% higher risk (hazard ratio: 1.84; 95% CI: 1.60 to 2.12). Neither cigarette smoking nor excess
weight was related to the risk of renal death (P0.10). The results were similar for cohorts in Asia and Australia. These
results suggest that primary prevention strategies for renal disease should focus on individuals with elevated blood
pressure, diabetes mellitus, and dyslipidemia. (Hypertension. 2009;54:509-515.)
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The increasing incidence of chronic kidney disease (CKD)and end-stage kidney disease (ESKD) represents a major
worldwide public health problem. The National Health and
Nutrition Evaluation Survey 1999–2004 in the United States
estimated that13% of US adults are affected by CKD and that
this proportion is continuing to rise.1 Elsewhere, survey data
from Australia, Europe, Thailand, China, and Japan indicate the
prevalence of CKD in the general population to be in the range
of 6% to 20%.2–6 Individuals with CKD have a reduced life
expectancy, and those with ESKD on hemodialysis have mor-
tality rates that are increased 20-fold compared with age- and
sex-matched individuals with normal kidney function.7
The number of patients initiating renal-replacement ther-
apy is also increasing in most countries,8,9 placing a substan-
tial burden on healthcare systems. Developed countries in
Asia have some of the highest rates of ESKD in the world,9
whereas less-developed countries are already unable to meet
the rising demand for dialysis treatment.10 There are 600
million people living in developing countries with no provi-
sion for renal replacement therapy, resulting in tens of
thousands of deaths annually from ESKD.11
The increasing incidence of CKD has been suggested to be
driven by 2 main factors: an aging global population and the
worldwide epidemic of type 2 diabetes mellitus. Several reports
from cohort studies in the United States12–15 and Japan16–18 have
also identified possible risk factors for the development and
progression of kidney disease, including suboptimal levels of
blood pressure, lipids, and body weight, as well as cigarette
smoking. However, quantification of the effects of putative risk
factors for renal death has been difficult to achieve, at least
partially because of underreporting of renal deaths.19
The high incidence and prevalence of kidney disease in the
Asia-Pacific region has been identified as a major public
health issue by the International Society of Nephrology, the
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Asian Pacific Society of Nephrology, and other groups.20 To
address this challenge, the Asian Forum of CKD Initiative
(APFCKDI) was established in 2007, with the investigation
of risk factors for kidney disease in the region as a major
priority. Hence, the aim of the current study was to determine
risk factors for renal death using data from 560 000
individuals from the Asia-Pacific region and, by doing so, to
highlight possible future targets for intervention.
Methods
Participating Studies
The design of the Asia Pacific Cohort Studies Collaboration
(APCSC), an overview of prospective observational studies, has
been described elsewhere.21 In brief, studies based in the Asia-
Pacific region with a prospective design and 5000 person-years of
follow-up were eligible for participation. Studies were excluded if
participants were selected on the basis of the presence of any disease
or risk factor. Studies were classified as Asian if based in China,
Hong Kong, Japan, South Korea, Singapore, or Taiwan or from
Australia for cohorts in that country. Studies participating in APCSC
were eligible for this analysis if data on renal death was available.
Measurement of Baseline Variables
Age, sex, and blood pressure at baseline were recorded for every
individual. Total cholesterol (TC), high-density lipoprotein choles-
terol (HDL-c), triglyceride level (TG), fasting blood glucose (FBG),
the presence or absence of diabetes mellitus (self-reported), body
mass index (BMI; weight in kilograms divided by the square of the
height in meters), and/or self-reported smoking status were also
recorded for some individuals. As the studies were initiated, and
sometimes recruited, over a long period of time, and developed
independently, the methods and instruments used for measuring risk
factors and reporting deaths varied both between and within studies.
Outcomes
All of the studies reported deaths by underlying cause. Outcomes
were classified according to the Ninth or 10th Revision of the
International Classification of Diseases (ICD; N, I, or E prefix
denotes ICD-10 coding system and all other coding is ICD-9). ICD-9
outcomes considered to indicate renal deaths in this analysis are
diabetes mellitus with renal manifestations (250.4), hypertensive
renal disease (403.x), renovascular disease (440.1), Wegener’s gran-
ulomatosis (446.4), acute glomerulonephritis (580.x), nephrotic syn-
drome (581.x), chronic glomerulonephritis (582.x), acute renal
failure (584.x), chronic renal failure (585.x), renal failure not
otherwise specified (586.x), renal sclerosis (587.x), small kidney
unknown cause (589), and unspecified disorders of kidney or ureter
(593.9). ICD-10 outcomes included are diabetic renal disease
(E1X.2), hypertensive renal disease (I12, I13, I15, and I15.1),
diseases of kidney and ureter (N00–29), acute renal failure (N179),
end-stage renal disease (N180), chronic renal failure (N189), renal
failure not otherwise specified (N19), impaired renal tubular function
(N259), and small kidneys (N279). Data regarding the need for
dialysis were not available. Sensitivity analyses were performed
restricting the outcomes to chronic renal failure and renal failure not
otherwise specified.
Statistical Methods
All of the analyses used individual-level participant data. For
continuous variables, individuals were classified according to ap-
proximately equal fourths, as measured at baseline. For each vari-
able, the hazard ratio (HR) for renal death was calculated using a
Cox proportional hazard model with corresponding 95% CIs derived
using floating absolute risks,22 with the reference group being those
in the bottom fourth (or top fourth for HDL-c). Log-linearities of the
associations with renal death were investigated through analyses by
fourths and, where there was a trend, were summarized through the
HR (and 95% CI) for a 1-SD increase (decrease for HDL-c). Log
transformation of TG values was performed to account for the
extreme right skewness of the data. All of the Cox models were
stratified by study and sex and adjusted by age.
To determine the association between “usual” level of each
continuous variable and renal death, the estimates were adjusted to
account for regression dilution bias. Similarly, to determine the
association between the usual levels of each variable categorized into
quartiles and renal death, the HR estimated for each quartile was
plotted against the usual mean in each category rather than against
the baseline mean.23 Information on the availability of repeat
measures for each variable is given elsewhere.21 These repeat
measures were used to estimate, for each variable, an attenuation
coefficient using a linear mixed-regression model that accounted
for the heterogeneity of variance between studies, within-subject
correlation, and the varying time intervals between measure-
ments. Regression attenuation coefficients were 1.9 for systolic
blood pressure (SBP), 2.1 for diastolic blood pressure (DBP), 1.7
for TC, 1.5 for HDL-c, 1.8 for log-TG, and 1.6 for FBG.
Likelihood ratio tests were used to assess the heterogeneity of the
effect of each variable on the risk of renal death by subgroups
defined by sex and region.
Results
Baseline Data
The 35 studies in the APCSC with data on baseline blood
pressure, composed of 560 352 individuals, are summarized in
Table 1. Compared with Australia, participants in the Asian
cohorts tended to be younger (45 versus 54 years of age) and
more likely to be women (47% versus 34%). Participants from
the Asian cohorts had lower baseline levels of SBP, BMI, and
TC. There was a higher prevalence of diabetes mellitus in the
Asian cohorts (7.1% versus 5.4%), although the mean FBG was
lower in cohorts from Asia compared with Australia (5.1 versus
5.6 mmol/L).
Outcomes
The median follow-up was 6.1 years in the Asian cohorts and 8.4
years in the Australian cohorts. During follow-up there were 420
renal deaths (Table 2). Most of the renal deaths were coded as
chronic renal failure or renal failure without further specifica-
tion, with a smaller proportion coded as glomerular disease or
acute renal failure. Of the reported renal deaths, 64.3% were in
Asia and 36.4% occurred among women.
Relationship Between Blood Pressure and the Risk
of Renal Death
Both SBP and DBP were positively and log-linearly associ-
ated with the risk of renal death (Figure 1). In age- and
sex-adjusted analyses, a 1-SD increment in SBP (19 mm Hg)
was associated with an 84% increase in mortality (HR: 1.84;
95% CI: 1.60 to 2.12; Figure 2). There was no evidence of
heterogeneity between Australia and Asia overall (P for
heterogeneity0.46), although there was some variation be-
tween countries within Asia (China HR: 1.80, 95% CI: 1.41
to 2.31; Japan HR: 1.79, 95% CI: 1.16 to 2.77; and South
Korea HR: 3.59, 95% CI: 2.21 to 5.83). There was some
evidence to suggest that the association was stronger among
men compared with women (HR: 2.08, 95% CI: 1.74 to 2.50
in men versus HR: 1.54, 95% CI: 1.23 to 1.92 in women;
P for heterogeneity0.04). The relationship persisted after
adjustment for the use of BP-lowering medications in the
102 900 participants with such data available, although the
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magnitude was slightly reduced (HR: 1.62; 95% CI: 1.28 to
2.05). Sensitivity analyses restricted to participants with
deaths attributed to renal failure or chronic renal failure
(n252) showed similar results (HR: 1.94; 95% CI: 1.62 to
2.14). Similar results were also obtained for DBP: a 1-SD
increment in DBP (11 mm Hg) was associated with a 57%
increase in the risk of renal death (HR: 1.57; 95% CI: 1.32 to
1.87; Figures 1 and 2).
FBG, Diabetes Mellitus and the Risk of
Renal Death
Among the 10 studies (227 746 participants; 85 renal deaths)
with information on FBG, there was a continuous (P0.001)
and positive association with renal death at FBG levels
4.5 mmol/L (Figure 1). In analyses adjusted for age and
sex, a 1-SD increment in FBG (1.42 mmol/L) was associated
with a 60% increase in the risk of renal mortality (HR: 1.60;
Table 1. Characteristics of Participating Cohort Studies
Study Name
Participants,
N
Age,
Mean,
y
Women,
%
Renal
Deaths
Follow-Up,
Median,
y
SBP,
Mean,
mm Hg
DBP,
Mean,
mm Hg
BMI,
Mean,
kg/m2
FBG,
Mean,
mmol/L
Diabetes
Mellitus,
%
TC,
Mean,
mmol/L
TG,
Mean,
mmol/L
HDL-c,
Mean,
mmol/L
Aito Town 1717 51 56.7 2 15.2 136 78 22.6 2.7 4.6 1.3 1.4
Akabane 1836 54 55.7 4 11.0 125 75 22.5 4.9 2.5 50 1.2 1.2
Anzhen 8378 54 55.1 7 4.3 129 78 23.9
Anzhen02 8957 36 11.6 19 27.9 123 78
Beijing Aging 2092 70 50.6 4 4.8 141 81 23.2 5.7 24.7 4.4 1.5 1.5
CVDFACTS 5730 47 55.3 9 6.0 118 75 23.5 2.7 5.0 1.2 1.3
East Beijing 1128 44 51.4 4 17.1 125 80 23.6 5.6
Fangshan 2625 47 66.5 4 3.6 136 81 24.4 5.0 7.1 4.6 1.5 1.4
Guangzhou
Occupational
167 377 42 21.7 31 7.3 115 75 22.6 5.1 10.5 5.3 1.5 1.3
Hisayama 1616 56 56.4 9 24.6 135 78 21.6 4.1
Hong Kong 3006 79 57.5 29 2.5 150 79 21.9 8.6 5.3 1.8 1.5
Huashan 1868 53 52.0 1 2.8 126 76 23.3 6.9 13.7 4.6 1.6 1.4
Kinmen 2793 63 48.1 5 2.9 137 81 23.4 8.6
KMIC 183 600 44 37.0 42 4.0 122 80 23.0 5.1 7.7 5.0
Konan 1226 52 55.4 3 6.4 130 78 21.9 5.3 12.6 4.9 1.1 1.6
Ohasama 10 811 54 54.5 19 2.7 130 72 22.6 1.2 5.0 1.7 1.5
Saitama 3624 55 62.2 1 11.0 135 80 22.4 1.7 5.0 1.5
Seven Cities Cohorts 9347 48 30.6 5 14.0 125 81 4.2
Shibata 2350 57 57.7 14 20.0 131 78 22.4 1.1 4.6
Shigaraki Town 3758 57 59.5 3 4.4 132 78 22.5 7.2 5.0 1.5 1.4
Shirakawa 4643 48 54.3 9 17.5 127 76 21.5 0.9 4.6 1.3
Singapore Heart 2325 41 49.0 5 14.6 123 76 23.5 5.3 11.4 5.9 1.4 1.0
Singapore NHS92 3305 39 51.8 1 6.2 118 69 23.2 9.7 5.4 1.4 1.3
Six Cohorts 19 387 45 46.7 14 9.0 119 76 21.2 4.2
Tianjin 9335 55 51.3 17 6.1 136 82 23.5
Xi’an 1695 44 33.7 1 19.7 126 83 4.6 1.2
Yunnan 6581 56 3.1 8 4.5 124 80 21.6 0.5 4.3 1.4
Total Asia 471 110 44.8 47.3 270 6.1 121 78 22.8 5.1 7.1 4.9 1.4 1.4
ALSA 1613 78 47.8 31 4.6 148 78 26.0 8.3 5.8 1.6 1.3
ANHF 9277 43 50.9 9 8.3 126 79 25.4 1.9 5.5 1.5 1.3
Busselton 7866 45 51.9 45 26.5 138 77 24.6 5.1 3.5 5.9 1.4 1.5
Canberra 833 77 45.5 11 9.4 145 82 6.8
Melbourne 41 286 55 58.9 29 8.5 138 77 26.9 5.7 5.4 5.5
Newcastle 5934 52 50.2 3 9.0 132 80 26.7 3.5 5.9 1.3
Perth 10 230 45 48.3 4 14.4 130 81 25.2 2.1 5.8 1.2 1.4
WA AAA Screenees 12 203 72 0 18 3.2 157 90 26.9 11.6
Total Australia 89 242 54 33.7 150 8.4 138.2 79 26.3 5.6 5.4 5.6 1.4 1.4
Total 560 352 46 35.9 420 6.8 124 78 23.6 5.2 6.7 5.1 1.4 1.4
A full list of participating studies is provided in the Appendix, available online at http://hyper.ahajournals.org.
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95% CI: 1.42 to 1.81). There was no evidence of regional
(P for heterogeneity0.14) or sex differences in the strength
of the association (P for heterogeneity0.19). Sensitivity
analyses restricted to those outcomes classified as renal
failure or chronic renal failure (n45) showed similar results
(HR: 1.56; 95% CI: 1.36 to 1.80).
In the 28 studies (333 388 participants; 301 renal deaths)
with information on diabetes mellitus status at study baseline,
individuals with a diagnosis of diabetes mellitus had 3
times the risk of renal death compared with those without
diabetes mellitus (HR: 3.69; 95% CI: 2.75 to 4.96). As with
the FBG analysis, there was no evidence that the association
differed by region or by sex (P for heterogeneity0.63 for
sex interaction and 0.44 for region interaction). There was
some variation in the relationship across different countries
within Asi (China HR: 8.34, 95% CI: 2.70 to 25.88; Japan
HR: 2.22, 95% CI: 0.58 to 8.42; South Korea HR: 5.64, 95%
CI: 2.06 to 4.85).
Cigarette Smoking, BMI, and Risk of Renal Death
Current smoking status was recorded for 526 331 individuals
(385 renal deaths) and BMI for 389 777 individuals (349
renal deaths). There was no clear evidence of an association
between current cigarette smoking and the risk of renal death
Table 2. Classification of Renal Deaths in APCSC Using ICD-9
and ICD-10
Cause of Death ICD Codes Events
Renal failure, chronic renal failure
not otherwise specified
585.x, 586.x, N189,
N191
252
Glomerular disease, including
diabetic nephropathy
250.4, 446.4, 580.x,
581.1, 581.9, 582.0,
582.8, 582.9, 583.x,
587.x, E1x0.2
69
Acute renal failure, not otherwise
specified
584.x, N179 40
Hypertensive renal disease,
renovascular disease
403.x, 440.1, I12,
I13, I15.x
27
ESKD, small kidneys 589, N180, N279 11
Tubulointerstitial disease N12, N259 5
Unspecified disorders of kidney
or ureter
593.9, N00 to N29 1
Not otherwise specified 15
Total renal deaths 420
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Figure 1. HRs, with 95% CIs, for renal death for
usual levels of SBP (millimeters of mercury), DBP
(millimeters of mercury), FBG (millimoles per liter),
and BMI (kilograms per meter squared) by fourths
(base: lowest fourth).
HR & 95% CI
0.8 1.0 1.5 2.0 3.0
1.60 (1.42-1.81)
1.20 (0.99-1.46)
1.84 (1.60-2.12)
1.50 (1.01-2.22)
1.41 (0.93-2.12)
1.00 (0.90-1.12)
FBG (+1.42 mmol/L)
TC (+1mmol/L)
SBP (+19 mmHg)
HDL-C(-0.43 mmol/L )
Log TG (+0.54 log(mmol/L))
BMI (+3.5 kg/m2)
HR & 95% CI
DBP (+11 mmHg) 1.57 (1.32-1.87)
Figure 2. HRs, with 95% CIs, for a 1-SD increment in SBP,
FBG, TC, TG, and BMI or a 1 standard decrement in HDL-c and
renal death.
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(HR: 0.81, 95% CI: 0.62 to 1.05). This result remained
unaltered by the exclusion of “ex-smokers” and by left-
censoring the data by 3 years to reduce the possibility of
reverse causality. There was no evidence of a linear associ-
ation between BMI and risk of renal death (HR: 1.00; 95%
CI: 0.90 to 1.12), a J-shaped relationship (Figures 1 and 2), or
an interaction by region.
Lipids and the Risk of Renal Death
Information from 343 989 individuals (n246 renal deaths)
contributed to the analysis for the association between TC
and the risk of renal death, whereas for TG and HDL-c there
were less data available (93 renal deaths among 74 925
individuals for TG and 79 renal deaths among 60 568
individuals for HDL-c). There was some evidence to suggest
that TC was positively associated with mortality risk in the
overall analyses, such that a 1-SD increment in TC
(1 mmol/L) was associated with a 20% greater risk of renal
death (HR: 1.20; 95% CI: 0.99 to 1.46; P0.059; Figures 2
and 3). This result was stronger when the outcomes consid-
ered were restricted to deaths attributed to renal failure or
chronic renal failure (56 deaths; HR: 1.46 95% CI: 1.13 to
1.69. There was no significant difference in the strength of the
association by region or sex (P for heterogeneity0.77 for
region interaction and 0.57 for sex interaction). There was
limited evidence to support a direct association between TG
levels with the risk of renal death (HR: 1.41; 95% CI: 0.93 to
2.12 per SD increment in log TG; P0.10; Figure 2).
There was a significant inverse association between levels
of HDL-c and risk of renal death (Figure 3). When the
relationship was examined continuously, a 1-SD decrease in
HDL-c corresponded with a 50% increase in the risk or renal
death (HR: 1.50; 95% CI: 1.01 to 2.22; Figure 2), with no
evidence of regional (P for heterogeneity0.16) or sex
differences (P0.92).
Discussion
Findings from the current study, based on prospective data
from 560 000 individuals from the Asia-Pacific region,
provide good evidence of direct and continuous associations
between both blood pressure and blood glucose and risk of
renal death. The magnitude of these associations was such
that an SD increment in blood pressure and blood glucose
was associated with an 80% and 60% greater risk of
mortality from renal disease, respectively. Similarly, among
those individuals with diabetes mellitus at study baseline, the
risk of renal death was 3 times that compared with
unaffected individuals. There was some evidence to suggest
that adverse lipid profiles may also predispose individuals to
death from renal disease. Raised levels of TC and low levels
of HDL-c were both independently associated with increased
risk of renal death, although the relationships were less strong
than with either blood pressure or blood glucose. Interest-
ingly, there was no evidence in the current study to implicate
excess body weight and cigarette smoking, which are both
important risk factors for cardiovascular disease, as being
associated with renal death.
The high incidence and prevalence of CKD in this region
have been identified as major public health issues leading to
interest in the delineation of factors associated with kidney
disease in the region as a priority.20 The large size of this
study bestows high power to identify factors associated with
renal death. Previous attempts to identify risk factors have
been hampered by several issues, not the least the large
number of renal events required to obtain reliable results and
the low rate of reporting kidney disease as a cause of death.
A recent study found that, although only 2% of death
certificates listed kidney disease as the primary cause of
death, it was listed as an associated condition in a further 7%
of deaths.19 As such, 1 in 10 death certificates cite kidney
disease, a proportion higher than for many major diseases,
including diabetes mellitus, lung cancer, breast cancer, and
colorectal cancer. This paucity of data has resulted in the
substantial underestimation of the importance of kidney
disease.
We observed blood pressure and glucose levels to be the
strongest predictors of renal death in this population. Al-
though these findings are not unexpected given that hyper-
tension and diabetes mellitus are among the leading causes of
ESKD worldwide,9 limited data are available on the relation-
ship between FBG levels, regardless of diabetes status, and
renal death. Analyses from the Framingham Offspring Study
showed a positive association between impaired fasting
glucose or impaired glucose tolerance and subsequent CKD,
although this was no longer significant after adjustment for
other vascular risk factors.23 In the current study, we observed
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Figure 3. HRs, with 95% CIs, for renal death for lipids, including usual levels of TC (millimoles per liter mmol/L), TG (millimoles per
liter), and HDL-c (millimoles per liter) by fourths (base: lowest fourth; for HDL-c, base: highest fourth).
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a continuous association between FBG and the risk of renal
death, suggesting that glucose may be an important aspect of
renal risk prediction and is likely to be a useful target for
screening and prevention strategies.
Our findings are consistent with a study from Japan where
a linear relationship between blood pressure and new-onset
ESKD was identified in 100 000 community-based individ-
uals undergoing health examinations,18 as well as other
studies that have identified a strong relationship between
blood pressure and the risk of ESKD,24,25 even after adjust-
ment for confounding by baseline kidney disease.13 The
demonstration, in a number of randomized trials, that blood
pressure and glucose-lowering therapies reduce the progres-
sion of CKD and the incidence of ESKD,24,26,27 further
underlines the importance of these factors. Because blood
pressure and glucose levels can be checked quickly and
cheaply, routine measurement of both should be a simple,
feasible, and highly cost-effective strategy28 for identifying
patients at increased risk for CKD that is likely to be
affordable for developed, as well as developing, countries.
The published literature on a direct association between
BMI and renal death is conflicting, with some studies
reporting a positive association between BMI and kidney
disease,18,29,30 whereas other studies, including the current
study, have observed no relationship either before or after
adjustment for other risk factors.31,32 It is possible that a long
duration of exposure is necessary for the relationship to
develop. For example, the relationship between BMI and
ESKD only became apparent in the Okinawa Study after 10
years of follow-up. Alternatively, other markers of body size,
eg, waist:hip ratio, may be better markers of risk than BMI, as
has been suggested recently.32
The relationship between lipid levels and the development
or progression of kidney disease has been an area of intense
recent interest. We observed a significant inverse relationship
with levels of HDL-c, and there was some suggestion of a
weak direct association with levels of TC. These results are
consistent with previous reports from the Physician’s Health
Study33 and the Helsinki Heart Study,25 which identified
higher total or low-density lipoprotein cholesterol levels, as
well as lower HDL-c levels, as risk factors for progressive
kidney disease. Additional support for a potential role for
lipids in the progression of kidney disease is provided by
posthoc analysis of the Cholesterol and Recurrent Events
Study34 and a recent meta-analysis35 that have suggested that
therapy with statins may slow the decline in kidney function
among people with CKD. The Study of Heart and Renal
Protection has randomized 9000 participants with kidney
disease to therapy with either simvastatin and ezetimibe or
matching placebo, and 5 years of follow-up is planned.
The lack of data on baseline kidney function and protein-
uria is an important limitation of our study, raising the
possibility that some participants in the studies may have had
CKD and making it impossible to assume that the relation-
ships that we have observed are causal. This issue of
confounding subclinical kidney disease is frequently cited in
related studies and is difficult to avoid. Nevertheless, the use
of the findings in identifying clinical markers for individuals
at high renal risk is unaffected. The effect of underreporting
of kidney failure as a cause of death would have been to dilute
the observed strength of the relationship between the risk
factors studied and death because of kidney disease. This is
likely to have been the case in the current study, where,
although only 1.7% of all deaths in APCSC were reportedly
attributed to renal disease, the true percentage is likely to be
several-fold higher. Similarly, the potential for competing
mortality risks (eg, cardiovascular causes of death) in some-
one who would have otherwise died of kidney disease may
have resulted in an underestimation of the strength of the
relationships. Finally, limited or no detail on drug therapy
was available for the majority of participants.
In summary, these findings extend the current understand-
ing in this important area by identifying a clear, continuous
association between both blood pressure and FBG and renal
disease, with some evidence of similar effects of dyslipidemia
in a large, prospective study. The results also provide evi-
dence that risk factors for CKD are likely to be equally
important in Asian and Western countries.
Perspectives
Population-wide campaigns targeting both blood pressure and
glucose levels offer the potential to significantly reduce renal
morbidity and mortality, particularly in developing countries,
where treatment availability for ESKD is very limited.
Screening for and treating these risk factors is simple,
cost-effective, and likely to be highly effective at reducing the
risk of death attributed to both kidney and cardiovascular
diseases. Public health and community-based programs
should be considered to lower the levels of glucose and blood
pressure so as to reduce the personal and socioeconomic
impacts of these devastating conditions.
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